¼¼ºê¶õ½ºº´¿ø ´ëÇÑÇ÷¾×ÇÐȸ AML/MDS ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-09-15±³À°ÀÏÀÚ : 2018-09-15
±³À°Àå¼Ò : ¼¼ºê¶õ½ºº´¿ø Á¾ÇÕ°ü 337È£ °ÀǽÇ
±³À°ÁÖÁ¦ :
AML/MDS ¿¬±¸È¸ ½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : AML/MDS¿¬±¸È¸
´ã´çÀÚ : Á¤¼¼¿µ
¿¬¶ôó : 02-533-1408
À̸ÞÀÏ :
seiyoung@yuhs.ac ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 60¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 4 ½Ã°£ 25ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 09:50~10:20 Long term use of hypomethylating agents for MDS Á¤ÁØ¿ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 10:20~10:50 JALSG AML/MDS/CMML Clinical observational study -Preliminary report of the MDS part- Kensuke Usuki(NTT Medical Center Tokyo)
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 10:50~11:20 Genetic mutations and decision-making of treatment options for MDS ±èÀ¯Áø(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 11:20~11:50 Preliminary report of AZA trial for high risk MDS, MDS212 on behalf of JALSG Yasushi Miyazaki(Nagasaki University)
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 11:50~12:05 Study Proposal (I)- Prospective study of the indUction Regimen for acute non-Promyelocytic myeloid Leukemia in Elderly Hypomethylating agents for favorable risk (PURPLE-H) ±èÇõ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 12:05~12:20 Study Proposal (II) - Beyond hypomethylating agent (HMA) failure in AML patients ¹Ú½Çºñ¾Æ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 12:20~12:35 Study Proposal (III) - Comparative study on MDS between Korea and Japan Yasushi Miyazaki(Nagasaki University)
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 13:30~13:55 Decision between epigenetic therapy and chemotherapy in patients with AML ÀÌÇý¿ø(±¹¸³¾Ï¼¾Å¸)
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 13:55~14:20 Genomics of Myeloid Malignancies Á¶¿µ¿í(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 14:30~14:55 Target Therapy ½Åµ¿¿±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 14:55~15:20 CAR-T Therapy, Immune Checkpoint and Vaccine Approaches in AML ÀåÁØÈ£(¼º±Õ°üÀÇ´ë)